Skip to main content
Epicel

NexoBrid is now Commercially available in the U.S.

Connect with Vericel

Vericel manufactures and markets two advanced cell therapy products for sports medicine and severe burn care in the United States and holds an exclusive license for North American commercial rights to NexoBrid®, a biological orphan product approved for eschar removal of severe thermal burns. Please use the links to the right to visit our product websites and learn more about our pipeline.

MACI
Learn More
Epicel
Learn More
Epicel
Learn More
MACI Arthro
Learn About the MACI Arthro Development Program
Vericel (VCEL) CEO On Sports Medicine & Severe Burn Care

Vericel (VCEL) CEO On Sports Medicine & Severe Burn Care

by Market On Close | November 9, 2023

Vericel (VCEL) specializes in sports medicine and severe burn care. VCEL manufacturers and markets two advanced cell therapy products. President and CEO Nick Colangelo joins Oliver Renick to give an overview of the company.

Read More

Botanical drug may outperform standard of care for treatment of severe thermal burns

Botanical drug may outperform standard of care for treatment of severe thermal burns

by Healio | September 29, 2023

Results from DETECT, the phase 3 study that supported the FDA approval of NexoBrid for the treatment of severe thermal burns, was recently published in the Journal of Burn Care & Research, Vericel announced in a release.

Read More

NexoBrid Now Available for Treatment of Severe Thermal Burns

NexoBrid Now Available for Treatment of Severe Thermal Burns

by Medical Professionals Reference (MPR) | September 21, 2023

NexoBrid (anacaulase-bcdb) is now available for eschar removal in adults with deep partial thickness and/or full thickness thermal burns...

Read More

Repairing the Body with Advanced Cell Therapies on Apple Podcasts

Repairing the Body with Advanced Cell Therapies on Apple Podcasts

by The Bio Report podcast | July 5, 2023

Nick Colangelo, president and CEO of Vericel, discusses the sports medicine and burn care markets the company is targeting, how its products are changing outcomes for patients, and the company’s plans for growth...

Read More

Vericel Corporation CEO Nick Colangelo on The Drill Down with Cory Johnson podcast

Vericel Corporation CEO Nick Colangelo on The Drill Down with Cory Johnson podcast

by The Drill Down podcast | June 7, 2023

Vericel Corporation CEO Nick Colangelo (VCEL) tells us about his company’s new cell-therapy that is changing the way we treat joint injuries and restore damaged skin tissue...

Read More

Vericel’s unique biopharma focus: Tackling unmet needs in sports medicine and burn treatment

Vericel’s unique biopharma focus: Tackling unmet needs in sports medicine and burn treatment

by Drug Discovery and Development | March 16, 2023

Vericel (Nasdaq:VCEL), a biopharma focused on sports medicine and severe burn care therapies, has a portfolio including the cartilage repair treatment MACI and the burn treatments Epicel and NexoBrid...

Read More

Vericel (VCEL) President & CEO On Sports Medicine & Severe Burn Care Therapies

Vericel (VCEL) President & CEO On Sports Medicine & Severe Burn Care Therapies

by TD Ameritrade Network | January 20, 2023

Vericel (VCEL) is a commercial-stage biopharma company that focuses on sports medicine and severe burn care therapies. President and CEO, Nick Colangelo discusses VCEL as it expects an accelerated commercial launch for arthroscopic MACI...

Read More

Vericel Shares Accelerated Launch Timeline for MACI Arthroscopic Program

Vericel Shares Accelerated Launch Timeline for MACI Arthroscopic Program

by Orthopedic Design & Technology (ODT) | January 11, 2023

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, has announced an accelerated launch timeline for MACI arthroscopic delivery, which is now anticipated to be launched in 2024...

Read More

Vericel Shares Up 13% on Preliminary FY22 Revenue Gain, Accelerated MACI Launch

Vericel Shares Up 13% on Preliminary FY22 Revenue Gain, Accelerated MACI Launch

by MarketWatch | January 10, 2023

Shares of Vericel Corp. increased 13%, to $27, on Tuesday after the company reported preliminary full-year 2022 revenue figures and said it expects an accelerated commercial launch timeline for its MACI arthroscopic delivery program...

Read More

Load More

NASDAQ: VCEL

$35.27 0.31 (0.89%)
Day High: $36.32
Day Low: $35.13
Volume: 243525
4:00 PM on
November 29, 2023
Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation

Vericel Company Presentation

Download the PDF

ESG Report

ESG Report

Download the PDF